Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Merck KGaA

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Merck KGaA's 2013 sales performance.

Merck KGaA

Pharma fears “lack of focus” on no-deal Brexit preparations

Pharma fears “lack of focus” on no-deal Brexit preparations supply. That is the view of Merck KGaA chief executive and President of European pharma's EFPIA, Stefan Oschmann, who says that the pharma industry has “been concerned by a certain ... While the situation at the EU-UK border remains unclear, two-thirds

Keytruda combo outshines Opdivo in kidney cancer

Keytruda combo outshines Opdivo in kidney cancer The data sets Merck &Co up to steal market share away from it rival, and the firm has already has filed the combination with the FDA. ... There is another contender in the checkpoint inhibitor field which could play a role: Pfizer and Merck KGaA’s

Industry aghast as EU Parliament backs biosimilar rule change

Industry aghast as EU Parliament backs biosimilar rule change In an open letter to European institutions, the president of the EFPIA trade body, Merck KGaA chairman and CEO Stefan Oschmann (below), says the EP’s provisions “diverge significantly from the

Advair generics and acquisitions to hit GSK in 2019

Advair generics and acquisitions to hit GSK in 2019 Earnings to decline as company transforms. GlaxoSmithKline yesterday demonstrated a new boldness in its business development, signing a multi-billion dollar alliance with Germany’s Merck on next-generation immunotherapy. ... acquisition of Tesaro and

BMS CEO tackles investor ‘frustrations’ on immuno-oncology

BMS CEO tackles investor ‘frustrations’ on immuno-oncology BMS was the pathfinder for the checkpoint inhibitor market with its CTLA4 inhibitor Yervoy (ipilimumab) and PD-1 blocker Opdivo (nivolumab), However, it has since lost ground to rival Merck ... And in the meantime, Opdivo/Yervoy’s lucrative position in

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
JPA Health Communications

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

How do companies prepare for reimbursement?
Valid Insight explore how to optimise your market access strategy during new product development, how to address payer concerns and prepare for reimbursement....
EHR clinical trials
Integrating electronic health records into clinical trials
How organisations are working to realise the research potential of EHRs...
Mike Elliott Gilead
Keeping up the fight against HIV and using the lessons to tackle other threats
Danny Buckland interviews Gilead’s Mike Elliott...

Infographics